Search tips
Search criteria 


Logo of f1000bioLatest ContentReportsReportsReports
F1000 Biol Rep. 2010; 2: 76.
Published online 2010 October 21. doi:  10.3410/B2-76
PMCID: PMC2981192

Treating aging: progress toward dietary restriction mimetics


During the last decade, biogerontologists have labored to understand the biological basis of the aging process by studying the genes and signaling pathways that regulate it. But the last year has seen a breakthrough in a different direction: toward treatments that might slow aging by mimicking the effects of dietary restriction.

Introduction and context

The effects of biological aging make up a sizeable proportion of the sum of human suffering. Aging is the predominant risk factor for the many horrible illnesses of later life, including cardiovascular disease, cancer, and neurodegenerative conditions such as Alzheimer’s disease. From a biological perspective, aging very much resembles a complex disease syndrome [1,2]. Because of this complexity, treatments for aging for have long seemed a forlorn hope. Moreover, the biological mechanisms of aging remain uncertain, although several promising hypotheses (e.g., that aging is caused by the accumulation of molecular damage) are currently under investigation [3]. Yet recent developments suggest that it might be feasible to treat aging even without fully understanding it.

In laboratory animals, it is possible to slow aging by using a variety of interventions - dietary, genetic, and pharmacological. For example, dietary restriction (DR), the measured reduction of food intake without starvation, can increase life span in organisms ranging from budding yeast (Saccharomyces cerevisiae) to dogs [4]. An important detail is that organisms under DR remain in a youthful state into late life and are resistant to aging-associated pathologies. This is consistent with the view of aging as a single, complex disease syndrome.

How does DR act to slow aging? One idea is that it affects nutrient-sensitive endocrine and intracellular signaling pathways that regulate aging. This is supported by studies of long-lived mutants (e.g., in the nematode worm Caenorhabditis elegans and the fruit fly Drosophila melanogaster). These studies have identified a network of nutrient- and stress-sensitive pathways that control aging. For example, mutations that reduce insulin/insulin-like growth factor-1 signaling (IIS) can increase adult life spans in worms (as much as 10-fold [5]), flies, and mice [6].

Were these DR-responsive pathways druggable, then, in principle, one could induce a DR-like state with resistance to aging-related disease. Such DR mimetic drugs could be an efficient way to improve late-life health and well-being in the future [7]. Several nutrient-sensing pathways, including IIS and the NAD+-dependent histone deacetylases (sirtuins), have been postulated to mediate the effects of DR [4]. Initial reports suggested that DR-induced longevity in yeast, worms, and flies was attributable to sirtuin activation, although this was subsequently challenged [4]. Also pursued were sirtuin-activating DR mimetic drugs such as the plant-derived polyphenol resveratrol. However, initial observations of sirtuin activation by resveratrol seem attributable to experimental artefact [8].

Recent studies have focused increasingly on a different nutrient-sensing pathway, which includes target of rapamycin (TOR) kinase and ribosomal S6 kinase (S6K). This pathway regulates cell growth, ribosome biogenesis, and protein turnover. Evidence from yeast, worms, and flies suggests that this pathway mediates the effects of DR on life span [4,6]. The proximal mechanisms involved remain unclear, although a candidate effector in yeast is the nutrient-sensitive transcription factor Gcn4 [9]. These findings raise a number of questions: Does the TOR/S6K pathway influence aging and mediate the effects of DR in mammals? Could drugs that target this pathway act as DR mimetics? Could these work in humans? This last year has seen progress in providing answers to all of these questions.

Major recent advances

First, it was shown that mutation-induced loss of mouse S6K1 increases life span and resistance to age-related pathologies [10]. Also, the physiology and gene expression of S6K1 mutant mice resembled those of wild-type mice subjected to DR. This suggests that, as in lower organisms, TOR/S6K signaling mediates DR effects. If this view is correct, then pharmacological inhibition of this pathway should recapitulate the effects of DR. Consistent with this, it was recently shown that the TOR inhibitor rapamycin (sirolimus) increases life span in flies [11] and also in mice, in which it was administered from mid-life onwards [12]. This perhaps suggests broad efficacy of DR mimetics consumed in later life.

S6K1 mutant mice also showed elevated activation of the nutrition-sensitive enzyme AMPK (adenosine monophosphate-activated kinase) [10], hinting that AMPK activation might promote longevity under DR. In C. elegans, longevity induced by loss of S6K (rsks-1) proved to be AMPK-dependent [10], supporting this view. The biguanide drug metformin, widely used as a treatment for type 2 diabetes, activates AMPK, inhibits TOR [13], and can induce a DR-like mRNA profile in mice [14]. It can also increase life span in both worms [15] and short-lived mouse strains [16] but not in male rats [17]. However, aging seems to be more difficult to slow in males; for example, effects on aging in S6K1 mutant mice are confined largely to females [10]. The greater phenotypic plasticity (in aging) that females seem to possess warrants further investigation.

Whether DR slows human aging remains unclear. However, studies were initiated in the late 1980s to discover whether DR can increase life span in primates (rhesus macaques). Interim results were reported recently and show that DR does reduce pathology and, potentially, mortality [18], consistent with results of an earlier, smaller trial [19].

Future directions

These recent discoveries motivate further studies that could pave the way to DR mimetic drugs for humans (Figure 1). Here, many questions remain. For example, does DR slow human aging? There are hints that it might. In Okinawa, Japan, a culture of DR is associated with an elevated frequency of centenarians [20], and in the US, those who practice DR show signs of improved cardiovascular health [21]. But further human studies, such as the ongoing CALERIE (Comprehensive Assessment of the Long-term Effect of Reducing Intake of Energy) study [22], are needed. Also, is there any evidence that metformin, rapamycin, or related compounds might slow human aging? Here, effects on diseases that are aging-related may provide clues. For example, DR reduces cancer incidence, at least in rodents and non-human primates, as do rapamycin and metformin [23]. Another issue is adverse side effects. Metformin can cause gastrointestinal upset, and rapamycin has immunosuppressant effects. To be a practical medical intervention, DR mimetics would need to be effective without inducing significant side effects. A final remaining question is how the TOR/S6K pathway controls aging. To answer this, the puzzle of aging itself will need to be solved.

Figure 1.
Dietary restriction (DR) mimetic studies from model organisms to humans


We thank Ivana Bjedov for reading the manuscript, and we acknowledge funding from a Wellcome Trust Strategic Award and the European Union.


adenosine monophosphate-activated kinase
dietary restriction
insulin/insulin-like growth factor-1 signaling
ribosomal S6 kinase
target of rapamycin


The electronic version of this article is the complete one and can be found at:


Competing Interests

The authors declare that they have no competing interests.


1. Caplan AL. Death as an unnatural process. Why is it wrong to seek a cure for aging? EMBO Rep. 2005;6:S72–5. [PubMed]
2. Gems D. Tragedy and delight: the ethics of decelerated ageing. Phil Trans R Soc. in press. [PMC free article] [PubMed]
3. Guarente LP, Partridge L, Wallace DC, editors. Molecular Biology of Aging. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2008.
4. Mair W, Dillin A. Aging and survival: the genetics of life span extension by dietary restriction. Annu Rev Biochem. 2008;77:727–54. doi: 10.1146/annurev.biochem.77.061206.171059. [PubMed] [Cross Ref]
5. Ayyadevara S, Alla R, Thaden JJ, Shmookler Reis RJ. Remarkable longevity and stress resistance of nematode PI3K-null mutants. Aging Cell. 2008;7:13–22. doi: 10.1111/j.1474-9726.2007.00348.x. [PubMed] [Cross Ref] F1000 Factor 3.0 Recommended
Evaluated by David Gems 08 Jan 2008
6. Kenyon C. The genetics of ageing. Nature. 2010;464:504–12. doi: 10.1038/nature08980. [PubMed] [Cross Ref]
7. Ingram DK, Anson RM, de Cabo R, Mamczarz J, Zhu M, Mattison J, Lane MA, Roth GS. Development of calorie restriction mimetics as a prolongevity strategy. Ann N Y Acad Sci. 2004;1019:412–23. doi: 10.1196/annals.1297.074. [PubMed] [Cross Ref]
8. Schmidt C. GSK/Sirtris compounds dogged by assay artifacts. Nat Biotech. 2010;28:185–6. doi: 10.1038/nbt0310-185. [PubMed] [Cross Ref]
9. Steffen KK, MacKay VL, Kerr EO, Tsuchiya M, Hu D, Fox LA, Dang N, Johnston ED, Oakes JA, Tchao BN, Pak DN, Fields S, Kennedy BK, Kaeberlein M. Yeast life span extension by depletion of 60s ribosomal subunits is mediated by Gcn4. Cell. 2008;133:292–302. [PMC free article] [PubMed] F1000 Factor 6.4 Must Read
Evaluated by Nektarios Tavernarakis 19 May 2008, Thomas Nystrom 28 May 2008
10. Selman C, Tullet JM, Wieser D, Irvine E, Lingard SJ, Choudhury AI, Claret M, Al-Qassab H, Carmignac D, Ramadani F, Woods A, Robinson IC, Schuster E, Batterham RL, Kozma SC, Thomas G, Carling D, Okkenhaug K, Thornton JM, Partridge L, Gems D, Withers DJ. Ribosomal protein S6 kinase 1 signalling regulates mammalian lifespan. Science. 2009;326:140–4. doi: 10.1126/science.1177221. [PubMed] [Cross Ref] F1000 Factor 3.3 Recommended
Evaluated by William H Colledge 12 Oct 2009, Robert Booth 26 Oct 2009, Daniel Gallie 30 Nov 2009
11. Bjedov I, Toivonen JM, Kerr F, Slack C, Jacobson J, Foley A, Partridge P. Mechanisms of lifespan-extension by rapamycin in Drosophila melanogaster. Cell Metab. 2010;11:35–46. doi: 10.1016/j.cmet.2009.11.010. [PMC free article] [PubMed] [Cross Ref]
12. Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, Nadon NL, Wilkinson JE, Frenkel K, Carter CS, Pahor M, Javors MA, Fernandez E, Miller RA. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009;460:392–5. [PMC free article] [PubMed] F1000 Factor 8.2 Exceptional
Evaluated by David Gems 03 Aug 2009, Heinz Osiewacz 31 Jul 2009, David Triggle 20 Aug 2009
13. Kalender A, Selvaraj A, Kim SY, Gulati P, Brûlé S, Viollet B, Kemp BE, Bardeesy N, Dennis P, Schlager JJ, Marette A, Kozma SC, Thomas G. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab. 2010;11:390–401. doi: 10.1016/j.cmet.2010.03.014. [PMC free article] [PubMed] [Cross Ref]
14. Dhahbi JM, Mote PL, Fahy GM, Spindler SR. Identification of potential caloric restriction mimetics by microarray profiling. Physiol Genomics. 2005;23:343–50. doi: 10.1152/physiolgenomics.00069.2005. [PubMed] [Cross Ref]
15. Onken B, Driscoll M. Metformin induces a dietary restriction-like state and the oxidative stress response to extend C. elegans Healthspan via AMPK, LKB1, and SKN-1. PLoS One. 2010;5:e8758. doi: 10.1371/journal.pone.0008758. [PMC free article] [PubMed] [Cross Ref]
16. Anisimov VN, Berstein LM, Egormin PA, Piskunova TS, Popovich IG, Zabezhinski MA, Tyndyk ML, Yurova MV, Kovalenko IG, Poroshina TE, Semenchenko AV. Metformin slows down aging and extends life span of female SHR mice. Cell Cycle. 2008;7:2769–73. [PubMed]
17. Smith DL, Jr, Elam CF, Jr, Mattison JA, Lane MA, Roth GS, Ingram DK, Allison DB. Metformin supplementation and life span in Fischer-344 rats. J Gerontol A Biol Sci Med Sci. 2010;65:468–74. doi: 10.1093/gerona/glq033. [PMC free article] [PubMed] [Cross Ref]
18. Colman RJ, Anderson RM, Johnson SC, Kastman EK, Kosmatka KJ, Beasley TM, Allison DB, Cruzen C, Simmons HA, Kemnitz JW, Weindruch R. Caloric restriction delays disease onset and mortality in rhesus monkeys. Science. 2009;325:201–4. doi: 10.1126/science.1173635. [PMC free article] [PubMed] [Cross Ref] F1000 Factor 9.0 Exceptional
Evaluated by David Gems 29 Jul 2009
19. Bodkin NL, Alexander TM, Ortmeyer HK, Johnson E, Hansen BC. Mortality and morbidity in laboratory-maintained Rhesus monkeys and effects of long-term dietary restriction. J Gerontol A Biol Sci Med Sci. 2003;58:212–9. [PubMed]
20. Kagawa Y. Impact of Westernization on the nutrition of Japanese: changes in physique, cancer, longevity and centenarians. Prev Med. 1978;7:205–17. doi: 10.1016/0091-7435(78)90246-3. [PubMed] [Cross Ref]
21. Fontana L, Meyer T, Klein S, Holloszy J. Long-term calorie restriction is highly effective in reducing the risk for atherosclerosis in humans. Proc Natl Acad Sci U S A. 2004;101:6659–63. doi: 10.1073/pnas.0308291101. [PubMed] [Cross Ref]
22. Redman LM, Veldhuis JD, Rood J, Smith SR, Williamson D, Ravussin E. The effect of caloric restriction interventions on growth hormone secretion in nonobese men and women. Aging Cell. 2010;9:32–9. doi: 10.1111/j.1474-9726.2009.00530.x. [PMC free article] [PubMed] [Cross Ref]
23. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005;330:1304–5. [PMC free article] [PubMed]

Articles from F1000 Biology Reports are provided here courtesy of Faculty of 1000 Ltd